WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September:
| Citi Biopharma Back to School Conference (Boston) | |
| Date: | Wednesday, September 3, 2025 |
| Time: | 10:30am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
| Morgan Stanley Global Healthcare Conference (New York) | |
| Date: | Monday, September 8, 2025 |
| Time: | 7:00am ET |
| Format: | Fireside Chat |
| Webcast: | Link |
The live webcasts of the fireside chats will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should contact their banking representatives.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.
Investor Contacts:
ProKidney
Ethan Holdaway
This email address is being protected from spambots. You need JavaScript enabled to view it.
LifeSci Advisors, LLC
Daniel Ferry
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.00 |
| Daily Change: | -0.04 -1.32 |
| Daily Volume: | 281,878 |
| Market Cap: | US$407.940M |
October 20, 2025 August 12, 2025 July 15, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
